Citations

Institution: Mayo Clinic Clear

Showing 10 of 108081 citations.

Ventilation-perfusion distribution in normal subjects
Beck, Kenneth C., Johnson, Bruce D. , Olson, Thomas P. , Wilson, Theodore A.

Journal of Applied Physiology | July 6, 2012 | Volume: 113 | Issue: 6 | Pages: 872-877

10.1152/japplphysiol.00163.2012 | PMID 22773767 Get It

Functional values of LogSD of the ventilation distribution (σV̇) have been reported previously, but functional values of LogSD of the perfusion distribution (σq̇) and the coefficient of correlation between ventilation and perfusion (ρ) have not been measured in humans. Here, we report values for σV̇, σq̇, and ρ obtained from wash-in data for three gases, helium and two soluble gases, acetylene and dimethyl ether. Normal subjects inspired gas containing the test gases, and the concentrations of the gases at end-expiration during the first 10 breaths were measured with the subjects at rest and at increasing levels of exercise. The regional distribution of ventilation and perfusion was described by a bivariate log-normal distribution with parameters σV̇, σq̇, and ρ, and these parameters were evaluated by matching the values of expired gas concentrations calculated for this distribution to the measured values. Values of cardiac output and LogSD ventilation/perfusion (V̇a/Q̇) were obtained. At rest, σq̇ is high (1.08 ± 0.12). With the onset of ventilation, σq̇ decreases to 0.85 ± 0.09 but remains higher than σV̇ (0.43 ± 0.09) at all exercise levels. Rho increases to 0.87 ± 0.07, and the value of LogSD V̇a/Q̇ for light and moderate exercise is primarily the result of the difference between the magnitudes of σq̇ and σV̇. With known values for the parameters, the bivariate distribution describes the comprehensive distribution of ventilation and perfusion that underlies the distribution of the V̇a/Q̇ ratio.
Amyloidosis
Gertz, Morie A.

New-Opathies | July 6, 2012 | Volume: No volume available | Issue: No issue available | Pages: 67-104

10.1142/9789814355698_0003 Get It

α ‐Actinin2 is required for the lateral alignment of Z discs and ventricular chamber enlargement during zebrafish cardiogenesis
Yang, Jingchun , Xu, Xiaolei

The FASEB Journal | July 6, 2012 | Volume: 26 | Issue: 10 | Pages: 4230-4242

10.1096/fj.12-207969 | PMID 22767232 Get It

α ‐Actinin2 (Actn2) is a predominant protein in the sarcomere Z disc whose mutation can lead to cardiomyopathy. However, the function of Actn2 in Z‐disc assembly and cardiomyopathy in vertebrates remains elusive. We leveraged genetic tools in zebrafish embryos to elucidate the function of Actn2. We identified a single Actn2 homologue expressed in the zebrafish heart and conducted loss‐of‐function studies by antisense morpholino technology. Although zebrafish Actn2 assembles early into the Z disc, depletion of actn2 did not affect the early steps of sarcomere assembly. Instead, Actn2 is required for Z bodies to register laterally, forming well‐aligned Z discs. Presumably as a consequence to this structural defect in the sarcomere, the depletion of Actn2 resulted in reduced cardiac function, primarily characterized as a reduced end‐diastolic diameter. The depletion of actn2 also significantly reduced the ventricle chamber size, due to both reduced cardiomyocyte (CM) size and CM number. Interestingly, reduced CM size can be rescued by the cessation of heart contractions. The genetic studies of zebrafish uncovered a function for actn2 in lateral registration of Z body. In actn2 morphant fish, the Z ‐disc defect sequentially affects cardiac function, which leads to morphological changes in the ventricle through a mechanical force‐dependent mechanism.—Yang, J., Xu, X. α ‐Actinin2 is required for the lateral alignment of Z discs and ventricular chamber enlargement during zebrafish cardiogenesis. FASEB J. 26, 4230–4242 (2012). www.fasebj.org
Celebrating dermatopathology and art: The First Annual Mayo Clinic Dermatopathology/Immunodermatology Art Competition
Lehman, Julia S. , Griffin, John R., Lehman, Julia S

Journal of Cutaneous Pathology | July 6, 2012 | Volume: 39 | Issue: 8 | Pages: 803-804

10.1111/j.1600-0560.2012.01932.x | PMID 22765838 Get It

Immunological Effects of [alpha]Gal-positive and [alpha]Gal Knockout Biological Heart Valves
McGregor, Christopher G.A. , Kogelberg, Heide, Byrne, Guerard W.

QScience Proceedings | July 5, 2012 | Volume: 2012 | Issue: 4 | Pages: No page available

10.5339/qproc.2012.heartvalve.4.61 Get It

Abstract As immune responses likely contribute to degeneration of bioprosthetic heart valves (BHVs), this nonhuman primate study compares the anti-Gal antibody response to BHVs from wild type (WT) pigs (current BHVs) and those from α-galactosyltransferase knockout (GTKO) pigs. Stented glutaraldehyde fixed BHVs from WT (n=4) and GTKO (n=3) pigs were commercially manufactured and implanted in the mitral position in nonhuman primates using standard surgical techniques. Recipients were treated with Lovenox (1mg/kg BID) for 5 weeks reducing to 1mg/kg daily for one week and then discontinued. Recipients were sensitized to the αGal antigen by immunization to match IgG levels found in humans. Serum antibody responses were monitored by ELISA. WT BHVs were explanted at 3 hours, 1 year, 2 years and the fourth is currently ongoing at 3 years. One GTKO BHV was explanted at 218 days. The remaining two GTKO BHVs are currently ongoing at 3 years. After immunization, circulating anti-Gal IgG levels were comparable in both groups at the time of implantation and were equal or greater than human levels. Anti-Gal antibody levels decreased in both WT and GTKO recipients after implantation. WT recipients, however, retained elevated levels (greater than 20% preimplant values) of anti-Gal IgG for at least the first year post implant. Conversely anti-Gal IgG levels in all GTKO recipients fell within one month and remained at less than 20% preimplant values. Analysis of the area under the curve showed a significant increase of anti-Gal IgG in the WT BHV group compared to GTKO BHV recipients (p<0.01). In this nonhuman primate model, the persistently and significantly (p<0.01) elevated levels of anti-Gal IgG antibody observed in WT but not GTKO BHV recipients, indicate continuing immune stimulation to the αGal antigen. Current commercially available BHVs are similarly known to contain αGal antigen. Anti-Gal antibody has been shown to increase calcification of processed pericardium in the rat implant model. These data support the hypothesis that preformed and induced anti-Gal antibody in BHV recipients may initiate an early immune response, which promotes subsequent calcification. BHVs made from GTKO pigs would eliminate this major xenoreactive antigen and provide a prosthesis with reduced immunogenicity. Such BHVs made from GTKO pigs may have greater durability and be potentially used in younger patients with more active immune systems.
Pharmacological Rescue of Mitochondrial Deficits in iPSC-Derived Neural Cells from Patients with Familial Parkinson’s Disease
Cooper, Oliver , Seo, Hyemyung , Andrabi, Shaida A. , Guardia‐Laguarta, Cristina , Graziotto, John J. , Sundberg, Maria , McLean, Jesse R., Carrillo‐Reid, Luis , Xie, Zhong , Osborn, Teresia, Hargus, Gunnar , Deleidi, Michela , Lawson, Tristan, Bogetofte, Helle , Pérez-Torres, Eduardo , Clark, Lorraine N. , Moskowitz, Carol, Mazzulli, Joseph R. , Chen, Li , Romero, Norma B. , Jiang, Houbo , Uitti, Ryan J. , Huang, Zhigao, Opala, Grzegorz, Scarffe, Leslie A. , Dawson, Valina L. , Klein, Christine , Ross, Owen A. , Trojanowski, John Q. , Marder, Karen, Przedborski, Serge , Krainc, Dimitri , Dawson, Ted M. , Isacson, Ole , Volpicelli‐Daley, Laura A. , Feng, Jian , Lee, Virginia M.‐Y. , Surmeier, Dalton James , Wszołek, Zbigniew K. , Ross, Owen A , Klein, Christine , Dawson, Valina L , Deleidi, Michela

Science Translational Medicine | July 4, 2012 | Volume: 4 | Issue: 141 | Pages: No page available

10.1126/scitranslmed.3003985 | PMID 22764206 Get It

Neural cells derived from induced pluripotent stem cells from patients with genetic forms of Parkinson’s disease provide insights into disease pathogenesis.
GLI1 Modulates EMT in Pancreatic Cancer—Response
Joost, Simon , Almada, Luciana L. , Rohnalter, Verena, Holz, Philipp Simon, Fernández-Zapico, Martín E. , Fernández‐Barrena, Maite G. , Lauth, Matthias

Cancer Research | July 4, 2012 | Volume: 72 | Issue: 14 | Pages: 3704-3705

10.1158/0008-5472.can-12-1468 Get It

Formic Acid-Based Direct, On-Plate Testing of Yeast and Corynebacterium Species by Bruker Biotyper Matrix-Assisted Laser Desorption Ionization–Time of Flight Mass Spectrometry
Theel, Elitza S. , Schmitt, Bryan H., Hall, Leslie, Cunningham, Scott A. , Walchak, Robert C., Patel, Robin , Wengenack, Nancy L. , Patel, Robin , Cunningham, Scott A

Journal of Clinical Microbiology | July 4, 2012 | Volume: 50 | Issue: 9 | Pages: 3093-3095

10.1128/jcm.01045-12 | PMID 22760034 Get It

ABSTRACT An on-plate testing method using formic acid was evaluated on the Bruker Biotyper matrix-assisted laser desorption ionization–time of flight (MALDI-TOF) mass spectrometry system using 90 yeast and 78 Corynebacterium species isolates, and 95.6 and 81.1% of yeast and 96.1 and 92.3% of Corynebacterium isolates were correctly identified to the genus and species levels, respectively. The on-plate method using formic acid yielded identification percentages similar to those for the conventional but more laborious tube-based extraction.
Maximizing medication therapy management services through a referral initiative
Imberg, Audrey J., Swanoski, Michael T., Renier, Colleen M. , Umbreit, Audrey , Sorensen, Todd D.

American Journal of Health-System Pharmacy | July 3, 2012 | Volume: 69 | Issue: 14 | Pages: 1234-1239

10.2146/ajhp110511 | PMID 22761079 Get It

The epidemiology of Alzheimer's disease: Laying the foundation for drug design, conduct, and analysis of clinical trials
Yaffe, Kristine , Tocco, Michael , Petersen, Ronald C. , Sigler, Catherine , Burns, Leah , Cornelius, Christel, Khachaturian, Ara S. , Irizarry, Michael C. , Carrillo, María C.

Alzheimer's & Dementia | July 3, 2012 | Volume: 8 | Issue: 3 | Pages: 237-242

10.1016/j.jalz.2011.12.005 | PMID 22546356 Get It

AbstractEpidemiological studies increasingly inform Alzheimer's disease (AD) public health impact, prevention strategies, drug targets, therapeutic interventions, and clinical trial design. For this reason, the Alzheimer's Association Research Roundtable convened an international group of AD experts with experience in conducting both observational and clinical trials for a meeting on October 19 and 20, 2010, in Washington, DC, to discuss the role of epidemiologic studies in AD research and therapeutic advances. Topics included wellness markers and risk factors, with a focus on special populations such as those at elevated risk, super agers, and underserved populations. Discussions also highlighted lessons learned from observational studies of aging, cardiovascular disease, and other disease areas, as well as how new technologies have enabled the gathering of data relevant to drug development and clinical trial conduct.